Choreo LLC Takes Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Key Points

• Choreo LLC acquired a new stake in Charles River Laboratories, purchasing 1,881 shares valued at approximately $283,000 in the first quarter.
• Several institutional investors significantly increased their holdings in Charles River Laboratories, with Rothschild Investment LLC growing its position by 480.0% in the same quarter.
• Analysts have mixed views on the stock, with one sell rating, eleven hold ratings, and five buy ratings, leading to a consensus rating of "Hold" and an average target price of $174.54.

Choreo LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 1,881 shares of the medical research company's stock, valued at approximately $283,000.

A number of other large investors have also bought and sold shares of the business. Teacher Retirement System of Texas acquired a new stake in Charles River Laboratories International during the 1st quarter worth $1,231,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Charles River Laboratories International by 15.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company's stock worth $952,000 after buying an additional 817 shares during the period. Janney Montgomery Scott LLC raised its stake in Charles River Laboratories International by 13.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company's stock worth $6,698,000 after buying an additional 5,148 shares during the period. GAMMA Investing LLC raised its stake in Charles River Laboratories International by 61.6% during the 1st quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company's stock worth $210,000 after buying an additional 533 shares during the period. Finally, Concurrent Investment Advisors LLC acquired a new stake in Charles River Laboratories International during the 1st quarter worth $213,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock traded down $2.75 during midday trading on Friday, reaching $166.89. 821,687 shares of the company's stock were exchanged, compared to its average volume of 1,288,905. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $236.88. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. The firm has a market cap of $8.20 billion, a price-to-earnings ratio of -256.75, a P/E/G ratio of 5.96 and a beta of 1.49. The stock's 50-day simple moving average is $152.96 and its 200 day simple moving average is $149.81.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The business had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. During the same quarter last year, the company posted $2.27 earnings per share. Charles River Laboratories International's quarterly revenue was down 2.7% on a year-over-year basis. On average, analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president owned 19,513 shares in the company, valued at $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently commented on the company. Evercore ISI raised their price objective on Charles River Laboratories International from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Mizuho dropped their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. Citigroup raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and lifted their price target for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. Wall Street Zen downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Saturday, July 5th. Finally, Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus price target of $174.54.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).